Nls Pharmaceutics Ag Stock Today
| NLSPW Stock | USD 0.01 0 11.11% |
Performance10 of 100
| Odds Of DistressOver 68
|
NLS Pharmaceutics is selling for under 0.01 as of the 30th of November 2024; that is 11.11 percent increase since the beginning of the trading day. The stock's lowest day price was 0.01. NLS Pharmaceutics has more than 68 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. Equity ratings for NLS Pharmaceutics AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of January 2021 | Category Healthcare | Classification Health Care |
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland. Nls Pharmaceutics is traded on NASDAQ Exchange in the United States.. More on NLS Pharmaceutics AG
Moving against NLS Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NLS Stock Highlights
| CEO President | Alexander MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
NLS Pharmaceutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NLS Pharmaceutics' financial leverage. It provides some insight into what part of NLS Pharmaceutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
NLS Pharmaceutics AG (NLSPW) is traded on NASDAQ Exchange in USA. It is located in The Circle 6, Zurich, Switzerland, 8058 and employs 14 people. NLS Pharmaceutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.77 M. NLS Pharmaceutics classifies itself under Biotechnology sector and is part of Health Care industry.
NLS Pharmaceutics AG has accumulated about 145.4 K in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check NLS Pharmaceutics Probability Of Bankruptcy
NLS Pharmaceutics Historical Income Statement
NLS Stock Against Markets
NLS Pharmaceutics Corporate Management
| MBA IV | Interim Officer | Profile | |
| Dr LLM | G Counsel | Profile | |
| MA MBA | Interim Officer | Profile | |
| Silvia Panigone | Interim Officer | Profile | |
| Sandy MD | Interim Officer | Profile | |
| Sharon Keys | Head Affairs | Profile | |
| Geert MD | Interim Officer | Profile |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.